New Insights into Pediatric Cancer Causes: The Role of Autoantibodies

The Search for New Causes of Pediatric Cancer

Researchers at the University of Bergen in Norway may have identified a previously unknown cause of pediatric cancer, potentially allowing for earlier detection in young children. Their findings indicate that children with pediatric cancer often produce autoantibodies targeting proteins essential for DNA repair. This discovery was published on October 14 in the journal Frontiers in Immunology.

Childhood cancer, though rare, typically manifests as blood cancers such as leukemia and lymphoma, or as tumors in the brain, spinal cord, and bones. In contrast, adult cancers often involve the lungs, breast, colon, prostate, and skin, suggesting different cellular origins between the two age groups.

Understanding Autoantibodies

Autoantibodies present a malfunction in the immune system. Unlike normal antibodies, which protect the body by targeting harmful viruses and bacteria, autoantibodies mistakenly attack the body’s own healthy tissues. This misidentification can lead to autoimmune diseases, including type 1 diabetes, lupus, Graves’ disease, multiple sclerosis, and rheumatoid arthritis.

The exact reason the immune system produces autoantibodies is unclear. Possible triggers include infections that stress the immune system, exposure to certain environmental toxins, or genetic factors.

Key Findings of the Study

Between 2014 and 2017, researchers analyzed tumor and blood samples from 175 children and adults with sarcoma or acute lymphoblastic leukemia. These samples were compared with those from healthy individuals, including blood donors and children from the Bergen Growth Study.

Children aged two to 19 with pediatric cancer showed significantly higher quantities of IgG class antibodies. These antibodies primarily targeted genes like RAD52, NUMA1, ALKBH7, APBB1, UNG, and MGMT, which are involved in DNA repair.

According to Professor Ola Myklebost, a study author, it was previously known that autoantibodies could be induced by mutated proteins in cancer. However, their study revealed an unexpected finding. The team found that patient autoantibodies could enter cells and nuclei, binding to these proteins outside the nucleus and preventing repair activities, thus increasing mutation rates.

This mechanism was substantiated by the observation that these autoantibodies were present eight times more frequently in schoolchildren who later developed cancer than in those who did not.

Implications and Future Research

Professor Myklebost emphasized that this represents an important new hypothesis regarding cancer development. The findings may apply not only to childhood cancer but possibly to young adults and occasionally adults.

Further research is needed to establish causality and the specific patterns of autoantibodies that are crucial. If confirmed, screening children for such antibodies could become a method to assess cancer risk. It might even be possible to eliminate the cells producing these antibodies or to block their activity.

Anastassia Serguienko, another study author, noted the potential role of penetrating autoantibodies in many human diseases. She called for future biomedical research to focus on understanding these antibodies’ mechanisms and biology.

The study by Anastassia Serguienko and colleagues was detailed in Frontiers in Immunology, highlighting the shared presence of pathogenic autoantibodies targeting DNA repair proteins in cancer patients and healthy children later diagnosed with cancer.